CD274 and non-small cell lung carcinoma: Almost in parallel, FDA also approved Pembrolizumab on October 2, 2015 for PD-L1-positive NSCLC, based on a large clinical trial, which assessed efficacy and safety of pembrolizumab in patients with advanced NSCLC (17).